New state law allows access to investigational drugs - McAfee & Taft
A new state law expands patient access to investigational drugs, potentially affecting drug manufacturers' distribution and compliance obligations.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 90 days of law enactment (check effective date in your state).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
State law now permits terminally ill patients to access investigational drugs outside of clinical trials, altering distribution channels and liability frameworks.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Review state-specific requirements for expanded access programs, update patient consent and adverse event reporting procedures, and ensure compliance with FDA's expanded access regulations.
Deadline
Within 90 days of law enactment (check effective date in your state).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines